Navigation Links
Inspire Announces Presentations at 2007 Association for Research in,Vision and Ophthalmology Annual Meeting

DURHAM, N.C.--(BUSINESS WIRE)--May 4, 2007 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that scientists and collaborators related to Inspire will present information from five abstracts at the 2007 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 6-10, 2007 in Ft. Lauderdale, Florida. These abstracts, which will be presented in poster sessions, are related to three of Inspire's programs, including bacterial conjunctivitis, dry eye and allergy.

Two poster presentations are related to AzaSite(TM) (azithromycin ophthalmic solution) 1%, a treatment for bacterial conjunctivitis, which was recently approved by the U.S. Food and Drug Administration.

-- Development of a Commercial Eye Drop Formulation of Azithromycin

L.M. Bowman, E. Si, J. Pang, M. Friedlaender

Sunday, May 6, 2007, 2:30 p.m. - 4:15 p.m.

-- Frequent Dosing With Topical 1% Azithromycin is Effective in Reducing Azithromycin-Resistant Pseudomonas aeruginosa Colony Counts in a NZW Rabbit Model

K.A. Yates, E.G. Romanowski, R.P. Kowalski, F.S. Mah, Y.J. Gordon

Tuesday, May 8, 2007, 8:30 a.m. - 10:15 a.m.

Three poster presentations are related to Inspire's development programs in dry eye disease and allergies.

-- Effect of Diquafosol on Ocular Surface Health in Dry Eye Disease

R. Brazzell, D.J. Kellerman, A. Schaberg, B.Yerxa, T. Durham

Sunday, May 6, 2007, 11:00 a.m. - 12:45 p.m.

-- A Correlation Between Central Corneal Staining and Visual Function in Patients Diagnosed With Dry Eye

G.W. Ousler, III, K. Brazzell, T. Durham, P. Walker, R.T. Anderson, M.B. Abelson

Sunday, May 6, 2007, 11:00 a.m. - 12:45 p.m.

-- The Pharmacological Properties of Epinastine on Histamine H2 and H4 Receptors

S.C. Wolff, K. Brubaker, R.C. Wright, J.L. Boyer

Monday, May 7, 2007, 3:00 p.m. - 4:45 p.m.

These po sters can be downloaded from Inspire's website, www.inspirepharm.com, following the conclusion of the conference. Additional information related to the ARVO conference can be obtained at www.arvo.org.

About Inspire

Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite(TM)(azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are trademarks owned by Allergan, Inc. AzaSite is a trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.

Forward-Looking Statements

The forward-looking statements in this news release relating to management's expectations and beliefs are based on preliminary information and management assumptions. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to product development, revenue, expense and earnings expectations, the seasonality of Elestat, intellectual property rights, adverse litigation developments, adverse developments in the U.S. Securities and Exchange Commission (SEC) investigation, competitive products, results and timing of clinical trials, success of marketing efforts, the need for additional research and testing, delays in manufacturing, funding, and the timing and content of decisions made by regulatory authorities, including the U.S. Food and Drug Administration. Further i nformation regarding factors that could affect Inspire's results is included in Inspire's filings with the SEC. Inspire undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof.

Contact

Investor Contact:
Inspire Pharmaceuticals, Inc.
Jenny Kobin,
VP, Investor Relations and Corporate Communications
919-941-9777, Ext. 219
or
Media Contact:
BMC Communications
Dan Budwick, 212-477-9007, Ext. 14


'"/>




Related medicine technology :

1. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Inspire Announces Presentations at Two European Scientific Conferences
3. Inspire Announces Positive Results of Phase 2 Trial of Epinastine Nasal Spray for Seasonal Allergic Rhinitis
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... MONTREAL , February 12, 2016 ... sofern nicht anders vermerkt)   ... Unternehmens http://www.telestatherapeutics.com abrufbar.    ... Website des Unternehmens http://www.telestatherapeutics.com ... Inc. (TSX:TST; PNK:BNHLF) veröffentlichte heute seinen Konzernabschluss ...
(Date:2/12/2016)... 12, 2016  SI-BONE, Inc., a medical device company that pioneered ... minimally invasive surgical (MIS) device indicated for fusion for certain disorders ... (NGS), the Medicare Administrative Contractor (MAC) covering the states of ... Maine , Massachusetts , Minnesota ... York , Rhode Island , ...
(Date:2/12/2016)... , Feb. 12, 2016  Memorial Hermann Health System ... Dwight Howard to bring a one-of-a-kind experience to ... Using cutting-edge technologies such as 360-degree video and Google ... virtually, then literally – giving the patients and their ... it was all caught on video . ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or “honeymoon” stage of a ... go out of their way to be romantic, and may exaggerate a strength or ... any online dating profile. , A recent study from Queendom.com , however, ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed ... top students from U.S. universities who will draw from Siemens’ deep knowledge ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... As a ... hectic schedule, a demanding job, and no time to decompress, Rabinowitz found herself drawn ... herself to meditation for its impact on her life, implementing a 20-minute-per-day meditation practice ...
(Date:2/12/2016)... ... February 12, 2016 , ... Every winter, someone is killed, injured ... West Penn Burn Center, part of the Allegheny Health Network, has partnered ... you the “Space Heaters Need Space” campaign. , “Space Heaters Need Space” ...
(Date:2/12/2016)... ... 12, 2016 , ... Erlanger Agency has announced a new partnership in its ... campaign focuses on the fight against breast cancer, fundraising for a local woman named ... . , Carmen is a loving single mother of two boys who also serves ...
Breaking Medicine News(10 mins):